Thromboelastographic Evaluation of Coagulation in Patients With Liver Disease
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The aims of this study were to investigate the parameters of thromboelastography (TEG) for evaluating coagulopathy and to reveal an association with disease severity and/or transfusion requirement in patients with chronic liver disease (CLD) in a clinical laboratory setting. Methods: We enrolled two groups of adult patients with cirrhotic (N=123) and non-cirrhotic liver disease (N=52), as well as 84 healthy controls. Reaction time (R), kinetic time (K), α-angle (α), maximal amplitude (MA), and coagulation index (CI) were measured with kaolin-activated citrated blood with the TEG 5000 system (Haemonetics Corporation, USA). Platelet count, prothrombin time international normalized ratio (PT INR), albumin, bilirubin, and creatinine were simultaneously measured. The CLD severity was calculated by using the Child-Pugh (C-P) and Model for End-stage Liver Disease (MELD) scores. Transfusion history was also reviewed. Results: All TEG parameters, PT INR, and platelet count in the cirrhotic group showed significant differences from those in other groups. At least one or more abnormal TEG parameters were identified in 17.3% and 44.7% of patients in the non-cirrhotic and cirrhotic group, respectively. Patients with cirrhotic disease had hypocoagulability. A weak correlation between R and PT INR (r=0.173) was noted. The TEG parameters could not predict CLD severity using the C-P and MELD scores. Patients with normal TEG parameters did not receive transfusion. Conclusions: Clinical application of TEG measurements in CLD can be informative for investigating coagulopathy or predicting the risk of bleeding. Further studies are warranted.
Abstract
Background: The aims of this study were to investigate the parameters of thromboelastography (TEG) for evaluating coagulopathy and to reveal an association with disease severity and/or transfusion requirement in patients with chronic liver disease (CLD) in a clinical laboratory setting. Methods: We enrolled two groups of adult patients with cirrhotic (N=123) and non-cirrhotic liver disease (N=52), as well as 84 healthy controls. Reaction time (R), kinetic time (K), α-angle (α), maximal amplitude (MA), and coagulation index (CI) were measured with kaolin-activated citrated blood with the TEG 5000 system (Haemonetics Corporation, USA). Platelet count, prothrombin time international normalized ratio (PT INR), albumin, bilirubin, and creatinine were simultaneously measured. The CLD severity was calculated by using the Child-Pugh (C-P) and Model for End-stage Liver Disease (MELD) scores. Transfusion history was also reviewed. Results: All TEG parameters, PT INR, and platelet count in the cirrhotic group showed significant differences from those in other groups. At least one or more abnormal TEG parameters were identified in 17.3% and 44.7% of patients in the non-cirrhotic and cirrhotic group, respectively. Patients with cirrhotic disease had hypocoagulability. A weak correlation between R and PT INR (r=0.173) was noted. The TEG parameters could not predict CLD severity using the C-P and MELD scores. Patients with normal TEG parameters did not receive transfusion. Conclusions: Clinical application of TEG measurements in CLD can be informative for investigating coagulopathy or predicting the risk of bleeding. Further studies are warranted.
참고문헌 (35)
- Tripodi A, "An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis", Gastroenterology, 137, pp.2105~2111 (2009)
- Lisman T, "Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment", Dig Surg, 24, pp.250~258 (2007)
- Amitrano L, "Coagulation disorders in liver disease", Semin Liver Dis, 22, pp.83~96 (2002)
- Basili S, "The coagulopathy of chronic liver disease : is there a causal relationship with bleeding? Yes", Eur J Intern Med, 21, pp.62~64 (2010)
- Tripodi A, "Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease", Aliment Pharmacol Ther, 26, pp.141~148 (2007)
- Mannucci PM, "Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No", J Thromb Haemost, 4, pp.721~723 (2006)
- Tripodi A, "The coagulopathy of chronic liver disease", N Engl J Med, 365, pp.147~156 (2011)
- Lisman T, "Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences", Blood, 116, pp.878~885 (2010)
- De Pietri L, "Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial", Hepatology, 63, pp.566~573 (2016)
- Shore-Lesserson L, "Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery", Anesth Analg, 88, pp.312~319 (1999)
- Schöchl H, "Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry", J Trauma, 67, pp.125~131 (2009)
- Kang YG, "Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation", Anesth Analg, 64, pp.888~896 (1985)
- Stravitz RT, "Potential applications of thromboelastography in patients with acute and chronic liver disease", Gastroenterol Hepatol, 8, pp.513~520 (2012)
- Tripodi A, "The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters", Thromb Res, 124, pp.132~136 (2009)
- Coakley M, "Transfusion triggers in orthotopic liver transplantation: a comparison of the thromboelastometry analyzer, the thromboelastogram, and conventional coagulation tests", J Cardiothorac Vasc Anesth, 20, pp.548~553 (2006)
- Bolliger D, "Principles and practice of thromboelastography in clinical coagulation management and transfusion practice", Transfus Med Rev, 26, pp.1~13 (2012)
- Wikkelsoe AJ, "Monitoring patients at risk of massive transfusion with Thrombelastography or Thromboelastometry: a systematic review", Acta Anaesthesiol Scand, 55, pp.1174~1189 (2011)
- Papatheodoridis GV, "Infection and hemostasis in decompensated cirrhosis: a prospective study using thrombelastography", Hepatology, 29, pp.1085~1090 (1999)
- Chau TN, "Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding", Gut, 43, pp.267~271 (1998)
- Pugh RN, "Transection of the oesophagus for bleeding oesophageal varices", Br J Surg, 60, pp.646~649 (1973)
- Wiesner R, "Model for end-stage liver disease (MELD) and allocation of donor livers", Gastroenterology, 124, pp.91~96 (2003)
- Evans JD, "Straightforward statistics for the behavioral sciences", pp.1996, Brooks
- Caldwell SH, "Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management", Hepatology, 44, pp.1039~1046 (2006)
- Lisman T, "Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment", Dig Surg, 24, pp.250~258 (2007)
- Salooja N, "Thrombelastography", Blood Coagul Fbrinolysis, 12, pp.327~337 (2001)
- Schiff ER, "Schiff’s diseases of the liver" (2007), Lippincott Williams & Wilkins
- Lowe GD, "Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use", Br J Haematol, 97, pp.775~784 (1997)
- Scarpelini S, "Normal range values for thromboelastography in healthy adult volunteers", Braz J Med Biol Res, 42, pp.1210~1217 (2009)
- Thalheimer U, "A comparison of kaolin-activated versus nonkaolin-activated thromboelastography in native and citrated blood", Blood Coagul Fibrinolysis, 19, pp.495~501 (2008)
- Karon BS, "Why is everyone so excited about thromboelastrography (TEG)?", Clin Chim Acta, 436, pp.143~148 (2014)
- Ben-Ari Z, "Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography", J Hepatol, 26, pp.554~559 (1997)
- Nascimento B, "Vitamin K-dependent coagulation factor deficiency in trauma: a comparative analysis between international normalized ratio and thromboelastography", Transfusion, 52, pp.7~13 (2012)
- Esch JS, "Platelet activation and increased tissue factor expression on monocytes in reperfusion injury following orthotopic liver transplantation", Platelets, 21, pp.348~359 (2010)
- Patel IJ, "Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions", J Vasc Interv Radiol, 23, pp.727~736 (2012)
- Mallett SV, "Clinical Utility of Viscoelastic Tests of Coagulation (TEG", ROTEM) in patients with liver disease and during liver transplantation, 2015, pp.41, 527~537